Close Menu

Biodesix

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has approved inclusion of Biodesix's VeriStrat proteomics test in its guidelines for non-small cell lung cancer, the Boulder, Colo.-based firm said today.

Agilent Technologies said this week that it has awarded its Agilent Thought Leader Award to Carlos Cordon-Cardo, a molecular pathologist at Mount Sinai Hospital

NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Highmark, a Blue Cross Blue Shield affiliate, for its Veristrat lung cancer test.

Drugmaker Aveo Oncology and test developer Biodesix entered into a partnership last week in which the two will share more equally the risks and profits of developing a personalized medicine product.

Proteomic diagnostics firm Biodesix and drug developer Aveo Oncology said this week that they are partnering to co-develop and commercialize Aveo's non-small cell lung cancer antibody drug ficlatuzumab and Biodesix's Veristrat as a companion test to predict best responders.

NEW YORK (GenomeWeb News) – Aveo Oncology and Biodesix announced today an agreement to develop Aveo's investigational non-small cell lung cancer drug ficlatuzumab alongside Biodesix's VeriStrat serum protein test as a companion diagnostic.

Insurer Aetna last month released a clinical policy bulletin providing an assessment of various available molecular-based cancer diagnostics and markers.

Biodesix this week received an EU CE Mark for its Veristrat specimen collection and shipping kit, allowing the company to make Veristrat results available to physicians in the EU and other countries recognizing the CE Mark.

Quest Offering Lynch Syndrome Genetic Panel Testing in US
Quest Diagnostics has launched a new testing service for gauging patients' risk of Lynch Syndrome, or hereditary nonpolyposis colorectal cancer.

Biodesix said this week that it has closed a structured debt financing with Capital Royalty Partners that provides the company with up to $20 million.

Pages

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.